Keensight Capital, a private equity manager specializing in pan-European Growth Buyout investments, has made an important announcement regarding its acquisition of a majority stake in Isto Biologics. Isto is a regenerative MedTech company that focuses on developing and manufacturing innovative orthobiologic products aimed at improving patient healing times. This acquisition comes from Thompson Street Capital Partners, which will continue to maintain a minority stake in the company, alongside Isto’s management team.
Isto Biologics was founded in 2016 and has quickly established itself in the market. The company offers a range of advanced products categorized as bone graft solutions. These solutions target six distinct functional areas, with a particular emphasis on allografts, which play a critical role in spinal bone repair. The products developed by Isto are currently utilized in over 400 hospitals and clinics, contributing to around 15,000 surgical procedures each month, mainly in the United States.
The support from Thompson Street Capital Partners has been instrumental in Isto’s growth trajectory. The company has significantly expanded its product offerings and increased its client base through both organic growth and strategic mergers and acquisitions. One notable example of this expansion is Isto’s acquisition of Advanced Biologics in 2023, which has further solidified its position in the regenerative medicine market.
Keensight Capital is well-equipped to help Isto Biologics build on its success and evolve into a global leader in the field of biomaterials for tissue regeneration. And Keensight plans to utilize its extensive international network and resources, along with its dedicated Performance team, to accelerate Isto’s growth strategy. This will involve not only enhancing its existing operations but also pursuing new opportunities through additional acquisitions.
KEY QUOTES:
“Building on our successful collaboration with TSCP, we are looking forward to working with Keensight as we enter the next phase of our growth. Our focus is on helping patients heal faster, and we are excited to bring our solutions to more hospitals and patients. Keensight’s deep sector expertise and global platform will help us to pursue an ambitious strategy to increase our geographical reach and product offerings.”
Don Brown, CEO, and Brian Barnes, President of Isto Biologics
“We have been investors in the biomaterials, orthopedics, spine and bone repair segments for over 20 years, and have been tracking Isto specifically for more than 5 years. Isto is the perfect example of a Keensight healthcare investment: a company that offers proven technology which is improving patient lives, while delivering sustainable and profitable growth. We are very excited to support Isto with its continued domestic success and international expansion.”
Amit Karna and David Piccoli, Partners at Keensight Capital
“Our partnership with Isto has been extremely successful. Together, we have been able to grow Isto’s suite of products, both organically and through acquisitions, and better leverage the Company’s commercial engine to expand the customer base. We have been fortunate to partner with the Isto team and are delighted to be continuing our relationship, alongside Keensight, in this exciting next stage of growth.”
Jesse Klein, Managing Director at Thompson Street Capital Partners
